ACell Inc. set terms of its initial public offering, in which the Maryland-based regenerative medicine company focused on severe wounds treatment looks to raise up to $80 million and be valued at up to $362.8 million. The company is selling 5 million shares in the IPO, which is expected to price between $14 and $16 a share. There will be 22.68 million shares outstanding after the IPO. UBS, Barclays, RBC Capital Market and SunTrust Robinson Humphrey are the lead underwriters. The recorded a net loss of $2.7 million on revenue of $23.68 million over the three months ended March 31, after net income of $66,000 on revenue of $24.15 million in the same period a year ago. The company is looking to go public at a time that the Renaissance IPO ETF has soared 61.7% over the past three months while the S&P 500 has advanced 15.3%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
- Key Words: For some, Biden’s $1.9 trillion COVID-19 rescue plan is a ‘lifeline’ — and couldn’t come a moment too soon - January 16, 2021
- NewsWatch: Biden’s ‘rescue America’ plan is big. How its trillions could help both Wall Street and Main Street - January 16, 2021
- TaxWatch: IRS says this tax season will be ‘one of the nation’s most important.’ Make note of these key dates - January 16, 2021